STOCK TITAN
  1. Home
  2. News
  3. SGHT

Sight Sciences, Inc. - SGHT STOCK NEWS

Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.

Sight Sciences, Inc., headquartered in Menlo Park, California, is a prominent medical device company dedicated to innovating and commercializing cutting-edge technologies for the treatment of prevalent eye diseases. The company operates through two main segments: Surgical Glaucoma and Dry Eye.

In the Surgical Glaucoma segment, Sight Sciences offers the OMNI Surgical System. This versatile device allows for both canaloplasty and trabeculotomy with a single corneal incision, aimed at reducing intraocular pressure in adults with primary open-angle glaucoma. The efficacy of OMNI has been demonstrated in multiple clinical trials, showing favorable outcomes in lowering intraocular pressure across various stages of glaucoma.

In the Dry Eye segment, the TearCare System is available for ophthalmologists and optometrists. This system helps manage dry eye disease through a single interventional eyelid procedure, providing significant improvements in the signs and symptoms of the condition over time.

Recent clinical trials have highlighted the effectiveness of these devices. For example, the GEMINI Study demonstrated successful results using OMNI combined with cataract surgery, and the SAHARA trial confirmed the benefits of TearCare compared to traditional treatments.

Financially, Sight Sciences derives key revenue from its Surgical Glaucoma segment. The company has seen active customer engagement, as evidenced by the number of OMNI and SION system orders, as well as TearCare SmartLids sales.

For investors and stakeholders, Sight Sciences continues to be a compelling entity with its relentless focus on reimagining eye care through transformative technologies. The company's commitment to improving patient outcomes and expanding its market presence underscores its significance in the ophthalmic medical device industry.

News

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT) won a $34 million patent infringement case against Alcon for their Hydrus Microstent in a positive jury trial verdict. The damages include $5.5 million in lost profits and $28.5 million in royalty damages. The verdict is subject to appeal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
none
-
News

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) will report its first-quarter financial results on May 2, 2024. The Company focuses on eyecare technology and aims to elevate the standard of care through innovative interventional technologies. The results will be discussed in a conference call on the same day, accessible through a live webcast on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
conferences earnings
-
News

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) announces results of a large-scale MIGS study comparing three leading technologies in glaucoma patients. OMNI technology shows significant IOP and medication reduction at 24 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
none
News

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) presents clinical data on OMNI Surgical System for glaucoma and TearCare System for dry eye disease at ASCRS Annual Meeting, showcasing long-term efficacy and support for primary treatment. Additional data reveals impressive outcomes at 36 months and superior results compared to existing treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
-
News

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) will present at the 23rd Annual Needham Healthcare Conference. The company focuses on eyecare technology, aiming to enhance patient care. The presentation will be on April 9, 2024, accessible via webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
conferences
-
News

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Rhea-AI Summary
Sight Sciences, Inc. (SGHT) reported strong financial results for 2023, with $81.1 million in total revenue, a 14% increase from 2022. Operating expenses were reduced by 20% in Q4 2023. The company also secured a $65.0 million credit facility. Clinical trials showed positive results for OMNI and TearCare technologies, enhancing patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
earnings
News

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Rhea-AI Summary
Sight Sciences, Inc. (SGHT) will report financial results for Q4 and full year 2023 on March 7, 2024. The company focuses on eyecare technology to enhance patient care. Investors can join the conference call for insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences earnings
-
News

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) launches the Ergo-Series of the OMNI Surgical System in Europe, enhancing minimally invasive glaucoma procedures. The technology aims to improve ergonomics and precision for surgeons, receiving positive feedback in the US and CE Mark approval for the EU market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
News

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

Rhea-AI Summary
Sight Sciences, Inc. (SGHT) announced the closing of a $65 million senior secured credit facility with Hercules Capital, Inc. The transaction included an immediate draw of $35 million, used to pay off the principal amount of the Company’s indebtedness to its previous secured lender. The new facility strengthens the company's balance sheet and enhances its ability to execute its strategic plan. The capital commitment aims to help Sight Sciences deliver on its mission to transform the treatment of eye diseases by treating the underlying causes. The credit facility terms include a 54-month maturity, with an interest-only period of 30 months, which can be extended to 36 months subject to certain performance milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
none
News

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) reported preliminary financial highlights for Q4 and full year 2023, with total revenue expected to be $18.6-18.8 million for Q4, a 9% decrease, and $80.9-81.1 million for the full year, a 14% increase. Cash and cash equivalents as of Dec 31, 2023, were approximately $138 million. The company's Q4 and full year 2023 financial results are preliminary and subject to audit, with complete results expected in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none

FAQ

What is the current stock price of Sight Sciences (SGHT)?

The current stock price of Sight Sciences (SGHT) is $5.205 as of November 1, 2024.

What is the market cap of Sight Sciences (SGHT)?

The market cap of Sight Sciences (SGHT) is approximately 262.6M.

What does Sight Sciences, Inc. do?

Sight Sciences, Inc. develops and commercializes surgical and nonsurgical technologies for treating prevalent eye diseases, focusing on glaucoma and dry eye disease.

What products are offered by Sight Sciences in the Surgical Glaucoma segment?

Sight Sciences offers the OMNI Surgical System, which facilitates canaloplasty and trabeculotomy to reduce intraocular pressure in patients with primary open-angle glaucoma.

What is the TearCare System?

The TearCare System is a product in Sight Sciences' Dry Eye segment designed for managing dry eye disease through an interventional eyelid procedure.

Where is Sight Sciences, Inc. headquartered?

Sight Sciences, Inc. is headquartered in Menlo Park, California, United States.

What were the findings of the GEMINI Study?

The GEMINI Study showed successful 12-month and 36-month results of the OMNI Surgical System combined with cataract surgery for glaucoma patients.

How does Sight Sciences contribute to treating dry eye disease?

Sight Sciences contributes to treating dry eye disease through its TearCare System, which has shown significant improvements in clinical trials.

What financial segment drives Sight Sciences' revenue?

Sight Sciences derives key revenue from its Surgical Glaucoma segment.

Who can I contact for investor relations at Sight Sciences?

For investor relations, contact Philip Taylor at Gilmartin Group via email at Investor.Relations@SightSciences.com or phone at 415.937.5406.

Are there any recent clinical highlights for Sight Sciences?

Yes, recent clinical highlights include the GEMINI Study for glaucoma and the SAHARA trial for dry eye disease, both showing favorable outcomes.

What trademarks does Sight Sciences hold?

Sight Sciences holds trademarks for Sight Sciences, TearCare, OMNI, and SION in the United States and other territories.

Stock SGHT logo
Sight Sciences, Inc.

Nasdaq:SGHT

SGHT Rankings

#3617 Ranked by Market Cap
N/A Ranked by Dividends

SGHT Stock Data

262.60M
50.31M
20.08%
50.9%
2.22%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MENLO PARK